Evonik has invested a double-digit million euro sum to increase production capacity for isobutene derivatives at its Marl location, according to Hydrocarbonprocessing.
The isobutene part of the C4 production network produces the petrochemical specialties tertiary butanol (TBA), di-isobutene (DiB) and 3,5,5-trimethylhexanal (TMH). The expansion, which was recently completed, increases capacity for isobutene derivatives by more than 50%. In addition, the expansion improves security of supply, flexibility and product quality for the customers.
Evonik's isobutene specialties are already in high demand as intermediates for the pharmaceutical and chemical industries. "As a leading European key supplier of high-purity isobutene derivatives, we willingly rise to the challenge of supporting our customers' dynamic growth and continuing to invest in product quality and security of supply," said Dr. Hinnerk Gordon Becker, head of the Specialties market segment at Evonik Performance Intermediates. "That's why, in June 2020, we already began the targeted expansion of our C4 Verbund and to eliminate existing bottlenecks in production and logistics. In this way, we are further expanding our position in the field of high-purity isobutene derivatives and also living up to our leadership role."
The conversion work has increased the purity of the 3,5,5-trimethylhexanal produced in Marl from around 88% to more than 95%. Customers will benefit from this: In future, they will be able to use the isobutene derivative directly in their own production process without having to purify it first.
As MRC reported earlier, in March, 2022, Evonik launched a new biosurfactant produced from renewable feedstocks.
The rhamnolipids are produced at Evonik’s plant in Slovenska Lupca, Slovakia following a triple-digit million-euro investment in the site, which is scheduled to be completed by the end of 2023. The biosurfactant range is made using feedstocks which are locally sourced and fully biodegradable, meeting demand for low-emission, low-impact cleaning products in the market.
We remind that in February, 2020, Dow and Evonik entered into an exclusive technology partnership. Together, they plan to bring a unique method for directly synthesizing propylene glycol (PG) from propylene and hydrogen peroxide to market maturity.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of EUR12.2 billion and an operating profit (adjusted EBITDA) of EUR1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: to improve life today and tomorrow.
MRC